Die Suchmaschine für Unternehmensdaten in Europa

EU-Förderung (8.000.000 €): Translational quantitative systems toxicology to improve the understanding of the safety of medicines - Sofia: 116030 Hor01.01.2017 EU-Rahmenprogramm für Forschung und Innovation "Horizont"

Auf einen Blick

Text

Translational quantitative systems toxicology to improve the understanding of the safety of medicines - Sofia: 116030

TransQST will develop a Quantitative Systems Toxicology (QST) approach, employing pre-existing data where possible, in order to yield new mechanistic insight into drug-induced toxicity. A central tenet of our programme will be to ensure the human physiological and pharmacological relevance of any test system that has been (or will be) used for generating the input data for modelling. By adopting this approach, we will be able to accurately interpret what happens when test systems are perturbed by drug exposure, and ensure translatability of modelling tools. Mechanistic translational biomarkers are a core aspect of our approach and will be applied in parallel with evidence for understanding how to develop, model and apply such biomarkers in a QST setting. The project is structured in 8 work packages to provide the following outcomes: curate the best available experimental data suitable for modelling adverse drug reactions; provide fit-for-purpose QST models that will address key toxicity measures for liver, kidney, heart and GI-tract; provide quantitative risk assessment for off-target toxicity in man based on in vitro and in vivo models; provide a quantitative mechanistic read-across from species (in vivo and in vitro) currently used for the toxicological evaluation of a new drug; provide definition and applicability of the human physiological relevance of preclinical test systems; provide a battery of translational biomarkers that can be used for quantitative read-across from in vitro systems to man and which relate to intracellular pathways (and systems) relevant to drug toxicity. Led by the University of Liverpool, TransQST brings together 14 partners, characterized by their scientific rigour and proven track record. Collectively they will enable achievement of the goals of the call, thanks to their complementarity, proven ability to work together (and with EFPIA partners), and their understanding of how to ensure the relevance of QST to human biology.


Geförderte Unternehmen:

Firmenname Förderungssumme
Abbvie Deutschland GmbH & Co. KG 0,00 €
Astrazeneca AB 0,00 €
Boehringer Ingelheim Internationalgesellschaft mbH 0,00 €
Certara UK Ltd. 484.600 €
Crown Bioscience Netherlands B.V. 325.354 €
Eli Lilly and Company Ltd. 0,00 €
Erasmus Universitair Medisch Centrum Rotterdam 220.500 €
European Molecular Biology Laboratory 1.093.089 €
Forschungsgesellschaft FUR Arbeitsphysiologie UND Arbeitsschutz e. V. 350.250 €
Fundacio Institut Hospital del Mar D Investigacions Mediques 900.525 €
Glaxosmithkline Research & Development Ltd. 0,00 €
Institut de Recherches Internationales Servier 0,00 €
Janssen Pharmaceutica N.V. 0,00 €
Orion Oyj 0,00 €
Sanofi-Aventis Recherche & Developpement 0,00 €
Synapse Research Management Partners SL 353.669 €
The Chancellor, Masters and Scholars of the University of Oxford 325.000 €
The University of Liverpool 1.161.914 €
Universitaetsklinikum Aachen 132.435 €
Universitatsklinikum Heidelberg 269.790 €
Universitat Wien 350.250 €
Universiteit Leiden 1.239.324 €
Universiteit Maastricht 793.300 €
Vertex Pharmaceuticals (Europe) Ltd. 0,00 €

Quelle: https://cordis.europa.eu/project/id/116030

Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider.